Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr

Sanofi India posts 27% growth in operating profits in Q1 2025

Standalone profit from operations for the quarter were Rs. 162 crores

Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr

The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr

The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025

Emcutix launches urea-based skin-care moisturizers ‘Ureaderm'

Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)

Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection

Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy

Artemis Medicare Services posts Q4 FY25 consolidated PAT at Rs. 23.02 Cr

The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025

Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr

The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025